Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04146376 · ClinicalTrials.gov registry record
Von Willebrand Factor in Pregnancy (VIP) Study
A clinical trial of Von Willebrand Diseases, sponsored by University of Washington.
- Recruiting
- Registry status
- 110
- Enrollment target
- 11
- Study locations
NCT04146376 is a study of Von Willebrand Diseases that is actively recruiting participants, run by University of Washington. The registered enrollment target is 110 participants, below the 716-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (85% lower). The trial reports 11 study locations across 11 states.
The verdict
NCT04146376, a study of Von Willebrand Diseases, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- 110 participants
- Enrollment target
- 11
- Study locations
Study Summary
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding. This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum period, followed by levels of 50-100% for 5-10 days after delivery, depending upon the route of delivery. The primary objective is to document the rate of primary postpartum hemorrhage (PPH). The secondary objective is to document further effectiveness outcomes and safety.
Conditions Studied
Interventions
- DRUG Tranexamic acid
- OTHER Use of a postpartum diary and additional blood draws
- DRUG VWF replacement therapy with Wilate
- OTHER Use of a postpartum diary and additional blood draws.
Study Locations (11)
Colorado
- University of Colorado - Aurora
Connecticut
- Yale University - New Haven
Florida
- University of Miami - Miami
Georgia
- Emory University - Atlanta
Illinois
- Bleeding & Clotting Disorders Institute - Peoria
Louisiana
- Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders - New Orleans
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- The Pennsylvania State University - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2019-10-12 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04146376
The ClinicalTrials.gov registry entry for NCT04146376 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 716-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (85% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Von Willebrand Diseases appearing as the primary indexed condition, and to 4 interventions - of which Tranexamic acid is the first listed.
NCT04146376 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Colorado, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT04146376 about?
NCT04146376 is a clinical study titled "Von Willebrand Factor in Pregnancy (VIP) Study". In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding. Th...
What is the current status of trial NCT04146376?
This trial is currently recruiting. The enrollment target is 110 participants. The study started on 2019-10-12. Estimated completion is 2026-12.
What conditions does trial NCT04146376 study?
This clinical trial studies the following conditions: Von Willebrand Diseases.
What interventions are being tested in trial NCT04146376?
The interventions under investigation include: Tranexamic acid (DRUG), Use of a postpartum diary and additional blood draws (OTHER), VWF replacement therapy with Wilate (DRUG), Use of a postpartum diary and additional blood draws. (OTHER).
Who is sponsoring clinical trial NCT04146376?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04146376 being conducted?
This trial has 11 study locations across Colorado, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
RECRUITING
-
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
RECRUITING · Phase 1
-
ATHN 9: Severe VWD Natural History Study
ACTIVE NOT RECRUITING
-
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.